These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8993503)

  • 21. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment.
    Hu Y; Lu X; Zhou G; Barnes EL; Luo G
    Mol Biol Cell; 2009 Jan; 20(1):114-23. PubMed ID: 18987339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
    Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
    Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase I inhibitor, camptothecin, induces apoptogenic signaling in human embryonic stem cells.
    García CP; Videla Richardson GA; Romorini L; Miriuka SG; Sevlever GE; Scassa ME
    Stem Cell Res; 2014 Mar; 12(2):400-14. PubMed ID: 24380814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.
    Inaba M; Mitsuhashi J; Kawada S; Nakano H
    Jpn J Cancer Res; 1994 Feb; 85(2):187-93. PubMed ID: 8144400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
    Huchet M; Demarquay D; Coulomb H; Kasprzyk P; Carlson M; Lauer J; Lavergne O; Bigg D
    Ann N Y Acad Sci; 2000; 922():303-5. PubMed ID: 11193907
    [No Abstract]   [Full Text] [Related]  

  • 27. Quercetin exerts synergetic anti-cancer activity with 10-hydroxy camptothecin.
    Tang Q; Ji F; Wang J; Guo L; Li Y; Bao Y
    Eur J Pharm Sci; 2017 Nov; 109():223-232. PubMed ID: 28822757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
    Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
    Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of camptothecin on topoisomerase I catalysis.
    Christiansen K; Westergaard O
    Ann N Y Acad Sci; 1996 Dec; 803():50-9. PubMed ID: 8993500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using yeast to understand drugs that target topoisomerases.
    Nitiss JL; Rose A; Sykes KC; Harris J; Zhou J
    Ann N Y Acad Sci; 1996 Dec; 803():32-43. PubMed ID: 8993498
    [No Abstract]   [Full Text] [Related]  

  • 31. DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Chen AY; Choy H; Rothenberg ML
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
    Borovitskaya AE; D'Arpa P
    Oncol Res; 1998; 10(5):271-6. PubMed ID: 9802062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins.
    Pommier Y
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):3-10. PubMed ID: 8633251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of topoisomerase I inhibition by anticancer drugs.
    Pommier Y; Tanizawa A; Kohn KW
    Adv Pharmacol; 1994; 29B():73-92. PubMed ID: 8996602
    [No Abstract]   [Full Text] [Related]  

  • 36. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of camptothecin.
    Liu LF; Desai SD; Li TK; Mao Y; Sun M; Sim SP
    Ann N Y Acad Sci; 2000; 922():1-10. PubMed ID: 11193884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid chromatin reorganization induced by topoisomerase I-mediated DNA damage.
    Sun M; Duann P; Lin CT; Zhang H; Liu LF
    Ann N Y Acad Sci; 2000; 922():340-2. PubMed ID: 11193917
    [No Abstract]   [Full Text] [Related]  

  • 39. [Mechanisms of acquired resistance to DNA topoisomerase I inhibitors].
    Okada K; Andoh T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1562-7. PubMed ID: 1651683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression and localization of Scl-70/DNA topoisomerase I vary throughout the cell cycle.
    Ramirez-Santoyo R; Lopez-Swiderski A; Avalos-Diaz E; Herrera-Esparza R
    Rev Rhum Engl Ed; 1998 Mar; 65(3):165-72. PubMed ID: 9574473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.